Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity for Neovascular Age-Related Macular Degeneration

This randomized clinical trial explores the effect of ranibizumab vs aflibercept in treating neovascular age-related macular degeneration with a treat-and-extend regimen for Australian participants in the RIVAL trial.

source https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2722672